Welcome to our dedicated page for Altimmune SEC filings (Ticker: ALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Peptide-based trial data, complex milestone payments, and frequent equity raises make Altimmune Inc’s disclosures tough to navigate. If you have ever searched “Altimmune SEC filings explained simply,” you already know the challenge: hundreds of pages packed with technical language and biotech accounting rules.
Stock Titan solves this problem with AI-powered summaries that turn every Altimmune quarterly earnings report 10-Q filing and Altimmune annual report 10-K simplified into plain-English insights. Our platform streams Altimmune Form 4 insider transactions real-time, flags cash-burn trends, and links each note in seconds—no more digging for footnotes on clinical trial spend. Need to monitor an unexpected disclosure? Our engine pushes alerts the moment an Altimmune 8-K material events explained notice hits EDGAR.
Whether you are comparing R&D expense trajectories or tracking Altimmune executive stock transactions Form 4, you will find every document in one place. Investors often ask, “Where can I review Altimmune proxy statement executive compensation details?” or “How should I interpret an Altimmune insider trading Form 4 transactions spike before data readouts?” Our expert commentary answers these questions and more, providing Altimmune earnings report filing analysis that ties revenue forecasts to trial timelines. By understanding Altimmune SEC documents with AI, you can evaluate dilution risk, anticipate capital needs, and follow pemvidutide’s clinical progress—all without wading through dense biotech jargon.
Altimmune, Inc. filed Amendment No. 1 to a Form S-3 shelf registration to register up to $400,000,000 of common stock, preferred stock, debt securities, warrants, and units. The amendment adds Rule 473(a) language for delayed effectiveness. The preliminary prospectus states the company may offer these securities from time to time, separately or in units, with specific terms and any underwriters or agents to be set in a future prospectus supplement.
Altimmune indicates net proceeds from any future sales will be used for general corporate purposes, including research and clinical development, working capital, and capital expenditures. No securities can be sold until a prospectus supplement is delivered after effectiveness. The company’s common stock trades on Nasdaq as “ALT.” As of November 5, 2025, Altimmune had 104,342,385 shares of common stock outstanding.
Altimmune (ALT) Form 4: Chief Financial Officer Gregory Weaver reported equity award activity on 11/11/2025. 18,750 shares of Common Stock were acquired at $0 via the vesting and settlement of Restricted Stock Units (transaction code M). To cover taxes on vesting, 5,672 shares were surrendered at $4.28 (transaction code F). Following these transactions, he directly holds 23,078 shares of Common Stock.
The filing shows 56,250 RSUs remaining after the reported activity. Per the award terms, RSUs vest over four years, with 25% vesting on November 11, 2025 and the remainder in equal annual installments over the next three years, subject to continued service.
Altimmune, Inc. filed a Form S-3 shelf registration to offer from time to time up to $400,000,000 of mixed securities, including common stock, preferred stock, debt securities, warrants and units. Any specific terms and sale methods will be set in a future prospectus supplement.
Sales may occur through underwriters, agents or direct transactions, after effectiveness. Net proceeds, if and when securities are sold, are intended for general corporate purposes, including research and clinical development, working capital and capital expenditures.
Altimmune’s common stock trades on Nasdaq under “ALT”; the shares closed at $3.75 on November 5, 2025. Shares outstanding were 104,342,385 as of November 5, 2025; this is a baseline figure, not the amount being offered.
Recent updates in the company overview include an amended Hercules term loan facility with availability increased to $125.0 million in tranches and a new $200.0 million ATM program with Leerink Partners.
Altimmune, Inc. established a new at-the-market equity offering program, allowing it to sell shares of common stock, from time to time at its sole discretion, for up to $200.0 million through Leerink Partners LLC as sales agent. Sales may be made on Nasdaq or other trading markets under an effective Form S-3 and related prospectus supplement, with a sales agent commission of up to 3.0% of gross proceeds.
The company also terminated its prior at-the-market facility, which authorized up to $150.0 million in sales through multiple agents. The new agreement contains customary terms, including indemnification and conditions, and does not require funds to be placed in escrow.
Altimmune, Inc. announced an at-the-market equity program to sell, from time to time, shares of its common stock for up to $200.0 million under a prospectus supplement, with Leerink Partners LLC acting as sales agent. Sales will be made as “at the market offerings” under Rule 415(a)(4) on Nasdaq (symbol ALT).
The sales agent will receive a commission of up to 3.0% of the aggregate gross sales price, and will be deemed an underwriter. Altimmune states it intends to use net proceeds for working capital and general corporate purposes, which may include R&D, clinical and regulatory activities, potential acquisitions or investments, and possible repayment or repurchase of securities.
Shares outstanding were 95,598,665 as of September 30, 2025. The company notes there is no escrow arrangement and no obligation for the sales agent to sell a specific amount; offerings may be suspended or terminated in accordance with the agreement.
Altimmune reported Q3 2025 results with a net loss of $19.0 million as operating expenses declined versus last year. Research and development was $15.0 million, reflecting lower MASH trial spend, while general and administrative was $5.9 million.
Liquidity strengthened. Cash, cash equivalents, restricted cash and short‑term investments totaled $210.8 million as of September 30, 2025. The company raised $112.1 million year‑to‑date via at‑the‑market sales and drew a $15.0 million first tranche under a term loan. Subsequent to quarter‑end, Altimmune raised $33.8 million more through the ATM and amended its Hercules facility to $125.0 million, drawing a second $20.0 million tranche; the amended loan bears the greater of 9.70% or prime plus 2.45% with a 30‑month interest‑only period.
Pipeline updates noted 24‑week IMPACT Phase 2b MASH topline results, Fast Track designation for pemvidutide in AUD, and ongoing Phase 2 trials in AUD and ALD. Shares outstanding were 104,254,173 as of October 31, 2025.
Altimmune, Inc. amended its loan agreement with Hercules Capital, increasing total term loan availability from $100.0 million to $125.0 million.
The facility provides up to four tranches: the first tranche of $15.0 million was drawn on May 13, 2025; the second tranche of $20.0 million was drawn at the November 5, 2025 amendment closing. A third tranche of up to $10.0 million becomes available upon achieving specified milestones, and a fourth tranche of up to $80.0 million is subject to lender approval.
The amended term loan bears interest at the greater of 9.70% per annum or the WSJ prime rate + 2.45%. The interest‑only period was extended to 30 months from May 13, 2025, which delays principal amortization. Altimmune also furnished a press release announcing third‑quarter results ended September 30, 2025.
Altimmune (ALT) reported a Form 4 for its Chief Financial Officer detailing new equity awards granted on October 1, 2025.
The filing shows stock options for 166,800 shares at an exercise price of $3.87, expiring on October 1, 2035, and 57,900 restricted stock units. The options vest over four years: 25% on October 1, 2026, then in equal monthly installments over the following 36 months. The RSUs vest over four years: 25% on October 1, 2026, then in equal annual installments for the next three years. The awards are reported as held directly.
Altimmune, Inc. insider Christophe Arbet-Engels, the company's Chief Medical Officer, reported awards on 10/01/2025 consisting of 450,000 stock options with a $3.87 exercise price and 150,000 restricted stock units (RSUs). The options vest over four years with 25% vesting on 10/01/2026 and the remainder monthly over the next 36 months, subject to continued service. The RSUs vest over four years with 25% on 10/01/2026 and the remainder in annual installments over three years and have no expiration date. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Altimmune, Inc. (ALT) filed a Form 3 reporting that Christophe Arbet-Engels, serving as Chief Medical Officer and an officer/director, has no securities beneficially owned in the company as of the event date 10/01/2025. The filing notes a Power of Attorney (Exhibit 24) and is signed by Gregory Weaver, as Attorney-in-Fact on 10/03/2025. This is an initial ownership statement required by Section 16; it discloses the reporting person’s relationship to the issuer and that no equity or derivative holdings are reported on the form.
FAQ
What is the current stock price of Altimmune (ALT)?
What is the market cap of Altimmune (ALT)?
